Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’ConnorJun. 12, 2018
Mario Saltarelli, M.D., Ph.D., Senior Vice President, Early Development and Neurology, Vertex Jack Hoppin, Ph.D., Co-Founder & Chief Executive Officer, Invicro Sue O’Connor, B.Sc. (Hons), Ph.D ., Vice President, Neuroscience Research, Bionomics
Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform TechnologyMay. 30, 2018
Research Conducted by MedImmune Shows the xB 3 Platform Efficiently Delivers Antibodies Across the BBB at Therapeutic Doses xB 3 Demonstrated Sustained Systemic PK Properties of the MedImmune Antibody Constructs and Demonstrated a Strong PK/PD Dose Dependent Relationship in a Neuropathic Pain Pre-Clinical Model The Research was Published in the Journal of Cerebral Blood Flow and Metabolism 1
Bioasis will present at the 25th Annual BIO International Convention, to be held June 4-7, 2018 at the Boston Convention & Exhibition Center.